Latest Islets of Langerhans Stories
Early attempts at islet cell transplantation to treat diabetes date to the nineteenth century, decades before the discovery of insulin in the 1930s.
Researchers at the University of Pittsburgh School of Medicine, funded by JDRF, have discovered that adult beta cells have the ability to replicate with the help of a protein known as cdk6.
MINNEAPOLIS and ST. PAUL, Minn., Dec. 11 /PRNewswire/ -- The University of Minnesota has received a $40 million pledge for diabetes research from the Richard M. Schulze Family Foundation.
Doctors have tricked mouse immune systems into thinking cells from a donor pancreas are theirs, bringing hope to diabetes patients, U.S.
SAN DIEGO, Nov. 10, 2008 (GLOBE NEWSWIRE) -- MicroIslet Inc.
Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes.
Geron Corporation (Nasdaq:GERN) today announced the publication of data showing the successful engraftment of human embryonic stem cell (hESC)-derived pancreatic islet-like clusters (ILCs) in diabetic mice.
BOTHELL, Wash., Oct. 24 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (BULLETIN BOARD: BLFS) , a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that MicroIslet Inc.
Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell(R), LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes.
DiaKine Therapeutics, developers of drugs designed to cause diabetes to go into remission, announced today that a Phase 2 Clinical Trial with the Company's lead drug candidate, Lisofylline (LSF), is underway.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.